Fig. 4.

Treatment with etanercept (decreasing T _α degradation rate by 10 fold), TGF- β injection (increasing its constitutive source by 10 fold), aducanumab (increasing the clearance rate of $A_{\beta }^o$ by 10 fold), and bindarit (increasing MCP-1 natural degradation by 10 fold). In a, the profiles of no treatment, bindarit and aducanumab coincide. In b, no treatment and bindarit coincide. The lowest curve in Fig. 4 a, and the highest curve in Fig. 4 b, correspond to the case where the curves of no treatment and several other drugs coincide; these drugs have negligible efficacy